The cannabis sector has rarely rewarded patience, and Tilray Brands is testing that thesis harder than most. Shares of the Nanaimo-based company have clawed back roughly 12.5 percent over the past week to trade near 6.39 CAD, a bounce that follows a slide to multi-year lows. But beneath the surface of a record fiscal 2026 performance sits a persistent cash burn that keeps forcing the company back to the equity market — and that dilution is quietly eroding the very value shareholders are betting on.
A Record Year With a Heavy Toll
Tilray posted net revenue of 915.5 million US dollars for fiscal 2026, an 11 percent increase and a company milestone. Yet the headline number flatters a more complicated reality. Operating losses consumed 69 million US dollars over the trailing twelve months before capital expenditures, while investing activities — including acquisitions — ate another 56 million. The GAAP net loss reached 105.2 million US dollars, with free cash flow landing at negative 98.6 million.
The adjusted figures tell a different story, and that divergence is worth examining. Adjusted EBITDA came in at 61.1 million US dollars, while adjusted net income reached 12.2 million. The gap between those metrics and the GAAP losses highlights just how much weight non-cash items and one-off charges carry in Tilray’s financial statements.
The Share Count Keeps Climbing
Here’s the arithmetic that should concern existing holders: the weighted average share count expanded 26 percent during fiscal 2026 to 111.8 million shares. In the fourth quarter alone, it grew another 18 percent to 115.5 million. Revenue growth of 11 percent simply cannot keep pace with share issuance growing at more than twice that rate.
Tilray raised 158.0 million US dollars through new share sales last fiscal year, net of costs. The equity program launched in April still has room for roughly 180 million US dollars in additional sales. Through July 28, the company had already collected 87 million US dollars gross at an average price of 6.77 US dollars per share. The one-for-ten reverse stock split in December did nothing to alter this fundamental dynamic — it merely repackaged the same dilution into fewer, higher-priced shares.
Beverages Are Carrying the Weight
The revenue mix explains why management keeps pushing the diversification narrative. Beverages and distribution contributed 50.9 million US dollars of the 57.2 million US dollar quarterly revenue increase. The beverage segment grew 61 percent year over year, distribution advanced 15 percent, while cannabis managed just 5 percent growth.
On an annual basis, non-cannabis operations now account for 71 percent of total revenue. But flip to the gross profit side and the picture inverts: cannabis delivers 41 percent of gross profit on just 29 percent of revenue. The legacy core business remains the most profitable segment — it’s simply getting smaller relative to the rest of the company.
Should investors sell immediately? Or is it worth buying Tilray?
CEO Irwin Simon frames this as intentional evolution. “The next chapter for Tilray will not be defined by a single product, a single market, or a single regulatory event,” he said alongside the results. Management has guided to adjusted EBITDA between 68 and 75 million US dollars for fiscal 2027, implying 11 to 23 percent growth, with revenue expected to cross the 1 billion US dollar threshold for the first time.
Wall Street Remains Divided
The analyst community hasn’t reached a consensus on how to value this transition. FactSet data shows three buy ratings and six holds, with no sells on the books. The median price target sits at 5 US dollars, roughly 12 percent above the current trading level, though the average of 7.47 US dollars is skewed by an outlier target of 19 US dollars. The lowest target on the street is 4.25 US dollars.
Individual calls span the spectrum:
- Derek Lessard at TD Cowen maintains a Buy with a 5 US dollar target
- Frederico Gomes at ATB holds with an 8 US dollar target
- Aaron Grey at Alliance Global holds with a 5 US dollar target
Meanwhile, earnings estimates for the current fiscal year have deteriorated. Analysts now project a loss of 0.47 US dollars per share for 2027, down from a negative 0.39 US dollar estimate just a month earlier.
The Balance Sheet Holds — For Now
Tilray ended May with roughly 235 million US dollars in cash, restricted funds, and marketable securities. Net debt by the company’s own definition stands at just 0.7 million US dollars. But that narrow measure obscures a fuller picture: total balance sheet liabilities run to about 227 million US dollars, with lease obligations adding another 171.5 million. Inventory and receivables together tie up roughly 490 million US dollars in working capital.
The recent share price recovery suggests investors are rewarding the strategic pivot toward beverages and distribution. Whether that momentum persists hinges on two things: hitting the 2027 EBITDA guidance, and narrowing the gap between adjusted profitability and actual cash generation. Until that second piece falls into place, the equity issuance machine will keep running — and every new share sold makes the growth story just a little bit harder to believe.
Ad
Tilray Stock: Buy or Sell?! New Tilray Analysis from August 4 delivers the answer:
The latest Tilray figures speak for themselves: Urgent action needed for Tilray investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 4.
Tilray: Buy or sell? Read more here...
